Case Study Reveals Progerstone Metabolites May Control Growth Hormones
Each year, doctors diagnose nearly 1.4 million new cases of breast cancer worldwide. A significant number of these are hormone receptor-negative tumors, meaning they lack estrogen (ER) and progesterone (PR) receptors. These cancers tend to be more aggressive, respond poorly to hormone therapies, and carry a higher risk of recurrence and death.
However, a groundbreaking study published in Breast Cancer Research provides new hope. It suggests that two progesterone metabolites—5α-dihydroprogesterone (5αP) and 3α-dihydroprogesterone (3αHP)—may have opposing roles in the development of these challenging cancers.
Study Overview
Show Section
Researchers aimed to understand how 5αP and 3αHP affect ER-/PR- breast cancer. Previous lab experiments had shown:
- 5αP promotes tumor growth
- 3αHP inhibits tumor growth
To build on this, scientists moved the research into a living system that mimics the human body more closely.
How the Study Was Conducted
Show Section
To investigate the effects of these metabolites in a living system, researchers used a mouse model. They implanted human ER-/PR- breast cancer cells (MDA-MB-231) directly into the mice. Once the tumors were established, they divided the mice into groups and treated each with one of the following: 5αP alone, 3αHP alone, both hormones, or no hormones as a control.
Throughout the study, the team tracked tumor activity—including how quickly tumors formed, how large they grew, and whether they shrank over time. In addition, they collected blood and tumor tissue samples to measure hormone levels. They used radioimmunoassays and gas chromatography-mass spectrometry to precisely analyze the concentration of 5αP and 3αHP.
What the Researchers Found
5αP Accelerated Tumor Growth
Mice treated with 5αP experienced faster tumor development. This confirms its strong tumor-promoting effect.
3αHP Reversed Tumor Growth
Mice treated with 3αHP not only resisted tumor growth, but in many cases, tumors actually shrank—even after initial stimulation by 5αP.
Balance Is Key
When both hormones were given together, they canceled each other out. This suggests the balance between 5αP and 3αHP may be crucial to regulating tumor behavior.
Tumor Tissue Showed Skewed Hormone Ratios
Tumor tissue contained 10 times more 5αP than 3αHP, regardless of treatment. This elevated 5αP:3αHP ratio may indicate that tumors produce more of the growth-promoting hormone to fuel their own expansion.
Why These Results Matter
Show Section
The study highlights that progesterone metabolites may play an active role in hormone receptor-negative breast cancers. Rather than being passive byproducts, they may drive or suppress tumor growth depending on their balance:
- 5αP appears to act as a tumor promoter.
- 3αHP may work as a natural tumor suppressor.
These findings open the door to new research and potential treatment pathways.
Meridian Valley Lab’s Role
At Meridian Valley Lab, we provide educational resources to help clinicians interpret emerging science around progesterone metabolites and hormone balance. While we do not currently offer a direct Progesterone Metabolites Profile, our comprehensive 24-hour Urine Ultimate Hormone Profile and other hormone panels (Plus Hormone Profile, Sex Hormone Profile) can support broader assessments of estrogen, progesterone, and metabolic patterns in complex cases.
Not sure which panel fits your patient? Contact our clinical team for guidance.
Reference
Click to View
- Wiebe J, Zhang G, Welch I, Cadieux-Pitre H. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors. Breast Cancer Research. 2013;15(3):R38.
